

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

10 Jun 2026

### The effect of boron based gel on the treatment of diabetic foot ulcers and infections

#### Protocol summary

##### Study aim

The effect of boron based gel on the treatment of diabetic foot ulcers and infections

##### Design

0.2% Chlorhexidine Dggluconate + 3% Pentahydrate Phenytoinate Gel will be used at least 20 and maximum 30 days. Control group: Treatment of topical ulcers in a method other than the procedure. With 95% confidence, the test power was 95% and using G-Power software, the minimum sample size required was 167. With an estimated 20 percent drop in sample size, the number increased to 400 total. The type of study is a type of interventional study and clinical trial.

##### Settings and conduct

A clinical, controlled, randomized, and blind clinical trial will be conducted. Classification of the wound and infection of the diabetic foot of the patient are based on the University of Texas system.. In the group treated with 0.2% chlorhexidine digluconate + 3% sodium pentahydrate Pentahydrate twice daily with or without systemic antibiotics is used depending on the patient's condition. In the control group, local ulcers are treated in a way other than the method. Total duration of use is 0.2% chlorhexidine digluconate + 3% sodium pentahydrate Pentahydrate at least 20 days but less than 30 days.

##### Participants/Inclusion and exclusion criteria

Patients who agree to enroll in the study Patients with diabetic foot ulcer/ or infection Patients older than 18 years of age and below 75 years Patients with or without type 1 diabetes mellitus or infection

##### Intervention groups

0.2% Chlorhexidine digluconate + 3% sodium glycol Phenytoinate Phenytoinate at least 20 and maximum 30 days with systemic antibiotics. Treatment of topical ulcers in a way other than mentioned

##### Main outcome variables

The aim of this clinical trial is to evaluate the effectiveness of 0.2% chlorhexidine digluconate + 3%

sodium pentahydrate pentahydrate sodium on wound healing and diabetic foot infections.

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20190212042686N1**

Registration date: **2019-04-16, 1398/01/27**

Registration timing: **registered\_while\_recruiting**

Last update: **2019-04-16, 1398/01/27**

Update count: **0**

##### Registration date

2019-04-16, 1398/01/27

##### Registrant information

##### Name

majid Mobasseri

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 41 3334 8939

##### Email address

mobasserim@tbzmed.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2018-12-06, 1397/09/15

##### Expected recruitment end date

2019-06-21, 1398/03/31

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

**Trial completion date**

empty

**Scientific title**

The effect of boron based gel on the treatment of diabetic foot ulcers and infections

**Public title**

The effect of boron based gel on the treatment of diabetic foot ulcers and infections

**Purpose**

Supportive

**Inclusion/Exclusion criteria****Inclusion criteria:**

Patients with diabetic foot ulcer/ or infection Patients who agree to enroll in the study. Patients older than 18 years of age and below 75 years Patients with or without type 1 diabetes mellitus or infection Patients who can be treated at outpatient clinics. Patients who are admitted to treatment.

**Exclusion criteria:****Age**

From **18 years** old to **75 years** old

**Gender**

Both

**Phase**

0

**Groups that have been masked**

- Participant
- Care provider

**Sample size**

Target sample size: **400**

**Randomization (investigator's opinion)**

Randomized

**Randomization description**

Given the fact that the sample size is the same in both groups, we use the Excel software and the formula = Rand () to randomize and to increase the precision and balance of the samples in the randomization (for any reason Patient will withdraw from the plan) We use several blocks per group. It will also be provided to the physician to cover the allocation of matte envelopes.

**Blinding (investigator's opinion)**

Double blinded

**Blinding description**

A gel that has an active ingredient in boron with a gel that does not have a substance and is used as a placebo is completely identical in terms of the shape and size of the container, and the gels themselves do not differ in terms of odor and color, and are completely indistinguishable. (This action was taken by the pharmaceutical company). The important point is that the patient is told that the gel used for the patient may be medication or medication. Clinicians and blind patients will be blinded.

**Placebo**

Used

**Assignment**

Parallel

**Other design features****Secondary Ids**

empty

**Ethics committees****1****Ethics committee****Name of ethics committee**

Ethics committee of Tabriz University of Medical Sciences

**Street address**

Tabriz - Azadi St. - Golghast St. - Central Office of Tabriz University of Medical Sciences

**City**

Tabriz

**Province**

East Azarbaijan

**Postal code**

5166614766

**Approval date**

2018-12-03, 1397/09/12

**Ethics committee reference number**

IR.TBZMED.REC.1397.727

**Health conditions studied****1****Description of health condition studied**

diabetic foot ulcer and infections

**ICD-10 code**

E12

**ICD-10 code description**

Malnutrition-related diabetes mellitus

**Primary outcomes****1****Description**

Wound area

**Timepoint**

25 to 30 days

**Method of measurement**

Clinical evaluation

**2****Description**

The size of the wound

**Timepoint**

25 to 30 days

**Method of measurement**

Clinical evaluation

**3****Description**

Depth of wound

**Timepoint**

25 to 30 days

**Method of measurement**

Clinical evaluation

**4**

**Description**

Infection in the wound

**Timepoint**

25 to 30 days

**Method of measurement**

Clinical evaluation

**Secondary outcomes**

empty

**Intervention groups**

**1**

**Description**

Intervention group: 0.2% Chlorhexidine Dggluconate + 3% Pentahydrate Phenytoinate Sodium Gel will be used at least 20 and maximum 30 days with or without systemic antibiotics.

**Category**

Treatment - Drugs

**2**

**Description**

Control group: Treatment for topical ulcers in a way other than mentioned

**Category**

Placebo

**Recruitment centers**

**1**

**Recruitment center**

**Name of recruitment center**

Imam Reza hospital and clinic of Salamat

**Full name of responsible person**

Majid Mobasseri

**Street address**

Golestan

**City**

Tabriz

**Province**

East Azarbaijan

**Postal code**

5166614766

**Phone**

+98 41 3337 3901

**Email**

mobasserimajid@yahoo.com

**Sponsors / Funding sources**

**1**

**Sponsor**

**Name of organization / entity**

Tabriz University of Medical Sciences

**Full name of responsible person**

A. Ghasem Jouyban

**Street address**

Golgasht Street

**City**

Tabriz

**Province**

East Azarbaijan

**Postal code**

5166/15731

**Phone**

+98 41 3335 9680

**Email**

research-vice@tbzmed.ac.ir

**Grant name**

**Grant code / Reference number**

**Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Tabriz University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

empty

**Country of origin**

**Type of organization providing the funding**

Academic

**Person responsible for general inquiries**

**Contact**

**Name of organization / entity**

Tabriz University of Medical Sciences

**Full name of responsible person**

Majid Mobasseri

**Position**

Professor

**Latest degree**

Medical doctor

**Other areas of specialty/work**

Endocrinology

**Street address**

Endocrine & Metabolism Department, Fourth Floor, Imam Reza Hospital, Golghast St, Tabriz, East Azarbaijan

**City**

Tabriz

**Province**

East Azarbaijan

**Postal code**

5166/15731

**Phone**

+98 41 3334 8939

**Fax**  
**Email**  
mobasserim@tbzmed.ac.ir

## Person responsible for scientific inquiries

### Contact

**Name of organization / entity**  
Tabriz University of Medical Sciences  
**Full name of responsible person**  
Majid Mobasseri  
**Position**  
Professor  
**Latest degree**  
Subspecialist  
**Other areas of specialty/work**  
Endocrinology  
**Street address**  
Golgasht st  
**City**  
Tabriz  
**Province**  
East Azarbaijan  
**Postal code**  
5166/15731  
**Phone**  
+98 41 3177 2047  
**Email**  
mobasserimajid@yahoo.com

## Person responsible for updating data

### Contact

**Name of organization / entity**  
Tabriz University of Medical Sciences  
**Full name of responsible person**  
Majid Mobasseri  
**Position**  
Professor  
**Latest degree**  
Subspecialist  
**Other areas of specialty/work**  
Endocrinology

**Street address**  
Golgasht  
**City**  
Tabriz  
**Province**  
East Azarbaijan  
**Postal code**  
5166/15731  
**Phone**  
+98 41 3177 2047  
**Email**  
mobasserimajid@yahoo.com

## Sharing plan

### Deidentified Individual Participant Data Set (IPD)

Yes - There is a plan to make this available

### Study Protocol

Yes - There is a plan to make this available

### Statistical Analysis Plan

Yes - There is a plan to make this available

### Informed Consent Form

Yes - There is a plan to make this available

### Clinical Study Report

Not applicable

### Analytic Code

Not applicable

### Data Dictionary

Not applicable

### Title and more details about the data/document

A portion of the data will be shared.

### When the data will become available and for how long

2019

### To whom data/document is available

University researchers and professors

### Under which criteria data/document could be used

For further studies

### From where data/document is obtainable

by Email

### What processes are involved for a request to access data/document

21/5000 Request via email

### Comments